Fouad Aoude, MD
Internal Medicine · Hopedale, MANPI 1871764399
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 431 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 431 payments — averaging $27.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- AbbVie$1K
- Johnson & Johnson$1K
- Lilly USA, LLC$825
- Esperion Therapeutics, Inc.$490
- plus $5K from 27 others
What the payments were for
- Food & beverage$11,85299%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 73 | $2,095 |
| Novo Nordisk | 43 | $1,493 |
| AbbVie | 55 | $1,265 |
| Johnson & Johnson | 22 | $1,125 |
| Lilly USA, LLC | 39 | $825 |
| Esperion Therapeutics, Inc. | 16 | $490 |
| Abbott | 7 | $474 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $404 |
| Boehringer Ingelheim | 20 | $378 |
| Eisai Inc. | 5 | $363 |
| Phathom Pharmaceuticals, Inc. | 14 | $328 |
| Novartis | 19 | $314 |
| E.r. Squibb & Sons, L.L.C. | 9 | $266 |
| Idorsia Pharmaceuticals US Inc | 12 | $252 |
| Amgen | 7 | $243 |
| Tolmar, Inc. | 9 | $218 |
| Exact Sciences | 10 | $200 |
| Merck | 9 | $181 |
| Pfizer | 7 | $180 |
| ANI Pharmaceuticals, Inc. | 7 | $172 |
| Xeris Pharmaceuticals, Inc. | 3 | $131 |
| GSK | 4 | $125 |
| Ardelyx, Inc. | 5 | $112 |
| Astellas Pharma US Inc | 2 | $95 |
| Baxter Healthcare | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $30 |
| Boston Scientific | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,932 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $52,127 |
| JardianceEmpagliflozin | 33 | $51,721 |
| OzempicSemaglutide | 27 | $36,137 |
| TradjentaLinagliptin | 16 | $22,316 |
| MounjaroTirzepatide | 18 | $20,236 |
| JanuviaSitagliptin Phosphate | 20 | $19,432 |
| XareltoRivaroxaban | 11 | $16,650 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,981 |
| Omeprazole | 274 | $4,562 |
| Atorvastatin Calcium | 367 | $4,446 |
| Metoprolol Succinate | 147 | $2,828 |
| Rosuvastatin Calcium | 86 | $2,645 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 99 | $2,467 |
| Tamsulosin Hcl | 119 | $2,306 |
| Lisinopril | 294 | $2,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $378 | $74,03749 claims |
| PfizerEliquis | $180 | $52,12742 claims |
| Novo NordiskOzempic | $1,493 | $36,13727 claims |
| Lilly USA, LLCMounjaro | $825 | $20,23618 claims |
| MerckJanuvia | $181 | $19,43220 claims |
| Johnson & JohnsonXarelto | $1,125 | $16,65011 claims |
| AstraZenecaBreztri Aerosphere | $2,095 | $13,98122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Hopedale
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.